Dexcom Expects Preliminary Q4 Revenue Of At Least $1.030B vs $1.01B Est.; FY23 Preliminary Revenue Expected to Be ~$3.62B vs $3.59B Est.
Portfolio Pulse from Benzinga Newsdesk
Dexcom has announced preliminary Q4 revenue of at least $1.030 billion, surpassing the estimated $1.01 billion. Additionally, the company expects its FY23 preliminary revenue to be around $3.62 billion, which also exceeds the estimated $3.59 billion.
January 08, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dexcom's preliminary Q4 revenue and FY23 revenue forecast both exceed analysts' estimates, indicating strong financial performance and potential growth.
Dexcom's announcement of higher-than-expected preliminary revenue for Q4 and the full year FY23 is a strong positive signal for investors. This outperformance is likely to instill confidence in the company's growth trajectory and could lead to a short-term increase in stock price as the market reacts to the positive news.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100